Arcoxia (ARCOXIA)

Active substance: EtoricoxibPharmacotherapeutic group: Non-steroidal anti-inflammatory drug (NSAID)

Composition and Pharmaceutical Form

Film-coated tablets:

• 60 mg — Green color;

• 90 mg — White color;

• 120 mg — Light green color.

Pharmacodynamics

Non-steroidal anti-inflammatory drug. Etoricoxib is a selective inhibitor of cyclooxygenase-2 (COX-2).

• Action: In therapeutic concentrations, it blocks the production of prostaglandins. It is characterized by anti-inflammatory, analgesic, and antipyretic actions.

• Special Features: Due to selective inhibition, inflammatory symptoms are reduced without affecting platelets or the gastrointestinal tract mucosa.

• Dosage: When used in daily doses up to 150 mg, it does not affect COX-1. The preparation does not affect the production of prostaglandins in the gastric mucosa or bleeding time. In conducted studies, no reduction in arachidonic acid levels or collagen-induced platelet aggregation was noted.

Contraindications

• Hypersensitivity to any component of the preparation;

• Complete or partial combination of bronchial asthma, recurrent nasal polyposis;

• Intolerance to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (including in anamnesis);

• Erosive-ulcerative lesions of the stomach and duodenum, active gastrointestinal bleeding;

• Cerebrovascular or other types of bleeding;

• Inflammatory bowel diseases (Crohn's disease, non-specific ulcerative colitis) in the acute phase;

• Hemophilia and other blood clotting disorders;

• Pronounced heart failure (NYHA II-IV);

• Pronounced hepatic failure (more than 9 points on the CHILD-PUGH scale) or active liver disease;

• Pronounced renal failure (creatinine clearance <30 ml/min), progressive kidney disease;

• Confirmed hyperkalemia;

• Period following aortocoronary bypass grafting;

• Peripheral arterial disease, cerebrovascular disease;

• Clinically expressed ischemic heart disease;

• Persistent arterial hypertension (uncontrolled hypertension greater than 140/90 mmHg);

• Pregnancy and lactation;

• Children under 16 years of age.

Special Instruction

The drug may have a negative effect on female fertility and is therefore not recommended for women planning a pregnancy.